Moderna, Inc.
320 Bent Street
Cambridge
Massachusetts
02141
United States
Tel: 617-714-6500
Fax: 617-583-1998
Website: http://www.modernatx.com/
Email: info@modernatx.com
About Moderna, Inc.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.
Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.
147 articles with Moderna, Inc.
-
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Tempus Data Analytics Firm Hits $2 Billion Valuation, One of a Handful of Chicago “Unicorns”
9/5/2018
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion. -
When people hear the word “unicorn” they may think of the mythical horse with a polished horn protruding from its brow. But in the world of investing, the term unicorn refers to a startup company worth more than $1 billion.
-
BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines
8/16/2018
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines. -
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
-
Oncorus, a biotechnology company based in Cambridge, Massachusetts, announced that Theodore (Ted) T. Ashburn had been chosen as the company’s new president and chief executive officer.
-
Convelo Therapeutics to Develop New Regenerative Medicines for Neurological Disease Characterized by Loss of Myelin
7/25/2018
Convelo Therapeutics, Inc. announced today that it has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS).
-
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
-
Moderna Opens New Manufacturing Site in Norwood, MA
7/17/2018
200,000 Square Foot State-of-the-Art Plant Built to Support Development of mRNA Medicines
-
The Novartis Institutes for BioMedical Research (NIBR) is ending its early-stage anti-infectives research programs located in Emeryville, California. As a result, the company expects to lay off about 140 employees.
-
Moderna Provides Mid-Year Corporate Update
7/11/2018
Updates on its portfolio of development candidates and progress on its 2018 priorities.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area. -
The biopharma industry generally views vaccines to be low-margin investments. From a public health perspective, however, vaccines can be one of the best investment dollars.
-
Former Akamai CEO Paul Sagan Joins Moderna’s Board of Directors
6/14/2018
Moderna Therapeutics announced that Paul Sagan has joined the company’s Board of Directors.
-
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
-
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...
5/14/2018
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners. -
Moderna Therapeutics and Merck expanded their 2016 collaboration deal to develop and commercialize personalized messenger RNA (mRNA) cancer vaccines. The new deal will include mRNA cancer vaccines that share antigens, including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
-
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
5/3/2018
Moderna Therapeutics and Merck announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
-
Billions of dollars are being invested in Boston-based life science companies.